These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 28192453

  • 1. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia BM, Galli M, Mussini C, Pinnetti C, Spagnuolo V, d'Arminio Monforte A, Ceccherini-Silberstein F, Andreoni M, Icona Foundation Study and mono-PI/r database Study Cohorts.
    PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453
    [Abstract] [Full Text] [Related]

  • 2. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR, Llibre JM, Bravo I, García-Rosado D, Cañadas MP, Pérez-Álvarez N, Paredes R, Clotet B, Moltó J.
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A, Icona Foundation Study Group.
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.
    Pharmacoeconomics; 2010 Aug; 28 Suppl 1():147-67. PubMed ID: 21182349
    [Abstract] [Full Text] [Related]

  • 6. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.
    AIDS; 2009 Aug 24; 23(13):1679-88. PubMed ID: 19487905
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.
    AIDS; 2008 Jul 31; 22(12):1389-97. PubMed ID: 18614861
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P, Prieto L, Jiménez De Ory S, Fernández Cooke E, Navarro ML, Ramos JT, Holguín Á, Madrid Cohort of HIV-1 Infected Children and Adolescents Integrated in the Paediatric Branch of the Spanish National AIDS Network (CoRISPe).
    PLoS One; 2017 Jul 31; 12(3):e0173168. PubMed ID: 28350802
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P, Mills A, Carpio F, Hsu R, DeJesus E, Pierone G, Henegar C, Fusco J, Fusco G, Wohlfeiler M.
    Clin Drug Investig; 2017 Jan 31; 37(1):51-60. PubMed ID: 27587070
    [Abstract] [Full Text] [Related]

  • 16. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
    Pernas B, Grandal M, Tabernilla A, Cid P, Pértega S, Castro-Iglesias Á, Mena Á, Margusino L, Pedreira JD, Poveda E.
    J Med Virol; 2016 Dec 31; 88(12):2125-2131. PubMed ID: 27218208
    [Abstract] [Full Text] [Related]

  • 17. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L, Cafaggi M, Colangeli V, Borderi M, Barchi E, Lanzafame M, Nicole' S, Degli Antoni AM, Bon I, Re MC, Viale P.
    Infect Dis (Lond); 2018 May 31; 50(5):352-360. PubMed ID: 29210336
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A, Marcelin AG, Calvez V.
    HIV Med; 2009 Nov 31; 10(10):620-6. PubMed ID: 19601995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.